Kyntra Bio
KYNB
213 hedge funds and large institutions have $2.63B invested in Kyntra Bio in 2019 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 82 increasing their positions, 64 reducing their positions, and 28 closing their positions.
28% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 64
21% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 28
17% more capital invested
Capital invested by funds: $2.25B → $2.63B (+$387M)
1% more funds holding
Funds holding: 210 → 213 (+3)
0.02% more ownership
Funds ownership: 2.8% → 2.82% (+0.02%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3% less call options, than puts
Call options by funds: $37.3M | Put options by funds: $38.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
+$42.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$28.9M |
| 3 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$18.5M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$14.3M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$9.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$55.5M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
-$11.7M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$10.8M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$10.5M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$9.28M |
KYNB Hedge Fund Activity: Q4 2019 in Review
213 of the 5,091 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q4 2019, worth a combined $2.63B — up 17% from $2.25B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new KYNB positions and 28 closed out — a net gain of 6 holders — while 82 added to existing stakes and 64 trimmed.
The largest buyer was Primecap Management, opening a new position worth an estimated $42.6M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $55.5M sold.
- 213 institutional investors held Kyntra Bio (KYNB) as of Q4 2019, up from 210 in Q3 2019.
- Funds reported $2.63B of Kyntra Bio stock for Q4 2019, up 17% quarter-over-quarter.
- 34 funds opened new Kyntra Bio positions in Q4 2019 and 28 closed out, a net change of +6 holders.
- The largest Kyntra Bio buyer in Q4 2019 was Primecap Management, an estimated $42.6M added.
- The largest Kyntra Bio seller in Q4 2019 was Adage Capital Partners, an estimated $55.5M sold.
Based on aggregated 13F filings for Q4 2019.